DELRAY BEACH, Fla., Jan. 18, 2011 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or the "Company") (Nasdaq:PSID) announced today that it has completed the development of its temperature-sensing microchip in conjunction with development partner RFID Solutions of Malaga, Spain. The microchip, which uses radio frequency identification (RFID) technology, is able to measure internal temperature within the body and communicate that temperature wirelessly to an external reader. The Company plans to integrate the temperature-sensing microchip with its Wireless Body™ platform.
As previously announced in November 2010, PositiveID teamed up with RFID Solutions, an advanced technical development group with innovative automated manufacturing and expertise in specialized requirements for sensors in RFID markets, to develop the temperature-sensing microchip for use in humans.
The Company expects its Wireless Body platform will continue to evolve with the addition of other bio-sensing capabilities, including glucose-sensing through its GlucoChip™, which is currently under development. The Wireless Body will be designed to enhance wellness and disease management, for diabetes and other chronic illnesses, by allowing healthcare systems to communicate with each other and deliver solutions to patients seamlessly.
Scott R. Silverman, Chairman and CEO of PositiveID, said, "When a person spikes a fever, it is a signal that their body is fighting an infection. By being able to continuously monitor temperature, it could provide an early warning to a caregiver at the onset of an illness. With the completion of this first bio-sensing microchip we will also explore other bio-sensing functions to integrate with the Wireless Body through our patent for an embedded bio-sensor system to improve remote patient monitoring."
The Wireless Body communication system is built on the Company's Patent No. 7,125,382 for an Embedded Bio-Sensor System.
About PositiveID Corporation
PositiveID Corporation develops and markets healthcare and information management products through its diagnostic devices and identification technologies, and its proprietary disease management tools. PositiveID's implantable healthcare devices and external hardware and software products are designed to communicate wirelessly to improve healthcare and the patient's quality of life. For more information on PositiveID, please visit .
The PositiveID Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7717
Statements about PositiveID's future expectations, including the Company's ability to integrate the temperature-sensing microchip with The Wireless Body to provide early warning at the onset of an illness; the likelihood that the Company's Wireless Body platform will continue to evolve with the addition of other bio-sensing capabilities, including glucose-sensing through its GlucoChip™, which is currently under development; the ability of the Wireless Body to enhance wellness and disease management, for diabetes and other chronic illnesses, by allowing healthcare systems to communicate with each other and deliver solutions to patients seamlessly; the likelihood that the Company will also explore other bio-sensing functions to integrate with the Wireless Body through its patent for an embedded bio-sensor system to improve remote patient monitoring; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include the Company's ability to successfully commercialize a temperature-sensing microchip and a glucose-sensing microchip, as well as The Wireless Body platform, as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 19, 2010, and the Company's 10-Qs filed on May 6, 2010, August 13, 2010, and November 12, 2010, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
CONTACT: Allison Tomek 561-805-8000 atomek@positiveidcorp.com Dan Schustack CEOcast 212-732-4300 dschustack@ceocast.com
